RT Journal Article
SR Electronic
T1 Perspectives for systems biology in the management of tuberculosis
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 200377
DO 10.1183/16000617.0377-2020
VO 30
IS 160
A1 Kontsevaya, Irina
A1 Lange, Christoph
A1 Comella-del-Barrio, Patricia
A1 Coarfa, Cristian
A1 DiNardo, Andrew R.
A1 Gillespie, Stephen H.
A1 Hauptmann, Matthias
A1 Leschczyk, Christoph
A1 Mandalakas, Anna M.
A1 Martinecz, Antal
A1 Merker, Matthias
A1 Niemann, Stefan
A1 Reimann, Maja
A1 Rzhepishevska, Olena
A1 Schaible, Ulrich E.
A1 Scheu, Katrin M.
A1 Schurr, Erwin
A1 Abel zur Wiesch, Pia
A1 Heyckendorf, Jan
YR 2021
UL http://err.ersjournals.com/content/30/160/200377.abstract
AB Standardised management of tuberculosis may soon be replaced by individualised, precision medicine-guided therapies informed with knowledge provided by the field of systems biology. Systems biology is a rapidly expanding field of computational and mathematical analysis and modelling of complex biological systems that can provide insights into mechanisms underlying tuberculosis, identify novel biomarkers, and help to optimise prevention, diagnosis and treatment of disease. These advances are critically important in the context of the evolving epidemic of drug-resistant tuberculosis. Here, we review the available evidence on the role of systems biology approaches – human and mycobacterial genomics and transcriptomics, proteomics, lipidomics/metabolomics, immunophenotyping, systems pharmacology and gut microbiomes – in the management of tuberculosis including prediction of risk for disease progression, severity of mycobacterial virulence and drug resistance, adverse events, comorbidities, response to therapy and treatment outcomes. Application of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach demonstrated that at present most of the studies provide “very low” certainty of evidence for answering clinically relevant questions. Further studies in large prospective cohorts of patients, including randomised clinical trials, are necessary to assess the applicability of the findings in tuberculosis prevention and more efficient clinical management of patients.We are at the doorstep of a new era in which systems biology approaches will contribute to the management of patients with tuberculosis including prediction of risk for disease progression and severity, response to therapy and treatment outcome. https://bit.ly/36DQegb